Get notified when LONA files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Selling Stockholder Offering With Negligible Company Proceeds (new) — The offering is entirely secondary, providing no meaningful capital to the company; the only potential proceeds are about $5,502 from warrant exercise.
  • License Agreement With Related Party Sermonix (new) — The pre-funded warrant was issued to Sermonix as partial consideration for the lasofoxifene license, and Sermonix is now selling the underlying shares, indicating a related-party transaction tied to the offering.
NASDAQ: LONA LeonaBio, Inc. S-1/A

LeonaBio registers resale of 5.5M shares by selling stockholder; company may receive only ~$5,502 from warrant exercise

Filed March 31, 2026 · ~1 min read

Key Changes

  • high

    This is a secondary offering: selling stockholder Sermonix may sell up to 5,502,402 shares, and LeonaBio receives no proceeds from those sales.

    The Offering verify on EDGAR →
  • medium

    LeonaBio could receive gross proceeds of about $5,502 if all pre-funded warrants are exercised for cash at $0.001 per share.

    Use of Proceeds verify on EDGAR →
  • medium

    Any net proceeds would fund working capital and advance lasofoxifene and other pipeline candidates.

    Use of Proceeds verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.

Partner

Trade LONA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 31, 2026 · How we verify